DAFNA Capital Management LLC Sells 59,319 Shares of KalVista Pharmaceuticals, Inc. $KALV

Key Points

• DAFNA Capital Management LLC reduced its stake in KalVista Pharmaceuticals by 7.3%, selling 59,319 shares, and now holds approximately 1.51% of the company, valued at $8.68 million.
• Insider selling activity includes CEO Benjamin L. Palleiko offloading 10,940 shares for around $144,627, reflecting a 2.75% decrease in his ownership.
• KalVista Pharmaceuticals recently reported a significant earnings miss, with EPS of ($3.69) compared to a consensus estimate of ($0.83), highlighting ongoing financial challenges for the company.

DAFNA Capital Management LLC cut its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 7.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 752,359 shares of the specialty pharmaceutical company's stock after selling 59,319 shares during the quarter. KalVista Pharmaceuticals makes up approximately 2.5% of DAFNA Capital Management LLC's portfolio, making the stock its 13th largest holding. DAFNA Capital Management LLC owned 1.51% of KalVista Pharmaceuticals worth $8,682,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Wells Fargo & Company MN increased its position in shares of KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock valued at $171,000 after buying an additional 4,543 shares during the period. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 1,494 shares during the period. Dimensional Fund Advisors LP raised its holdings in KalVista Pharmaceuticals by 14.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock valued at $5,895,000 after buying an additional 89,001 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Finally, Nebula Research & Development LLC purchased a new stake in KalVista Pharmaceuticals in the fourth quarter worth $98,000.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright raised their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. JMP Securities lifted their price target on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Tuesday, July 8th. Finally, Leerink Partners lifted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Down 0.9%

Shares of KalVista Pharmaceuticals stock traded down $0.13 during trading hours on Wednesday, reaching $14.16. 1,418,230 shares of the stock traded hands, compared to its average volume of 781,849. The company has a 50 day moving average price of $13.58 and a 200 day moving average price of $12.54. The firm has a market capitalization of $712.81 million, a price-to-earnings ratio of -3.84 and a beta of -0.10. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the company posted ($1.07) earnings per share. Sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,336 shares of the business's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the completion of the sale, the insider directly owned 122,505 shares in the company, valued at $1,644,017.10. The trade was a 1.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 10,940 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $144,626.80. Following the transaction, the chief executive officer owned 386,858 shares of the company's stock, valued at approximately $5,114,262.76. This trade represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,710 shares of company stock valued at $880,764. Corporate insiders own 4.30% of the company's stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).